Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled date : 2021 - 04 - 13 save search
Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction
Published: 2021-04-13 (Crawled : 13:00) - biospace.com/
BHC | $8.595 -0.41% 880K
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: -0.5%
dry eye disease eye eye disease results topline phase 3 trial
Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
NVCR | $12.49 -1.81% 350K
|
Health Technology
|
| O: 50.14%
H: 10.14%
C: -0.34%
lung cancer cancer phase 3 trial dmc recommendations decades
Geron Announces First Patient Dosed in IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
GERN | $3.575 3.62% 2.8M
|
Health Technology
|
| O: -0.7%
H: 2.13%
C: 1.42%
fibrosis phase 3 trial
Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
LLY | $749.215 -0.21% 1.4M
|
Health Technology
|
| O: -0.35%
H: 1.36%
C: 0.75%
RIGL | $1.13 -1.74% 520K
|
Health Technology
|
| O: 13.27%
H: 5.14%
C: 3.14%
covid phase 2 positive topline trial
Zai Lab Partner Novocure Announces Update on Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Published: 2021-04-13 (Crawled : 12:00) - globenewswire.com
ZLAB | $14.43 1.62% 300K
|
Health Technology
|
| O: 13.59%
H: 7.76%
C: 7.53%
NVCR | $12.49 -1.81% 350K
|
Health Technology
|
| O: 50.14%
H: 10.14%
C: -0.34%
lung cancer cancer phase 3 trial
501JT, Senior Clinical Trial Manager
Published: 2021-04-13 (Crawled : 01:00) - fatetherapeutics.com
FATE | $5.475 -2.93% 1.3M
|
Health Technology
|
| O: 0.01%
H: 6.6%
C: 5.19%
trial
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
WISA 4 | $5.33 204.57% 190M
|
Electronic Technology
TPET | $0.5189 124.54% 38M
|
n/a
SXTC | $1.78 52.14% 33M
|
Health Technology
JAGX | $0.1771 49.07% 540M
|
Health Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
MCBC | $13.74 38.37% 1.6M
|
Finance
FNCH | $2.98 32.74% 400K
|
Professional, Scientific, and T...
PALI | $5.51 32.45% 28M
|
Manufacturing
VERO | $0.804 31.8% 110K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.